Despite a pullback in the cannabis sector due to the actions of Attorney General Jeff Sessions, moving to roll back an Obama administration policy of leaving cannabis as a state’s rights issue, we feel strongly that the cannabis train cannot be stopped, even by the federal government. That’s why we’re still tracking companies like GB Sciences Inc (OTCMKTS:GBLX) closely.
The company has a high tech growing facility, where it has hundreds of high powered grow lights and attains maximum yields, through its own admission, in part due to keeping a pleasant ‘vibe’ around its plants. It’s quite easy to have such a vibe when you’ve got such promising product under cultivation, as referenced by the company’s most recent press.
GB Sciences Inc (OTCMKTS:GBLX) recently announced the development of a cannabis strain that has an extremely high THC concentration, and also has a specifically-defined terpene profile, and provided commentary from management.
The team was gratified to receive hard test results that verified their goal. The plant produced a THC-a content of 35.119%, as well as β-myrcene levels of 2.18% and β-caryophyllene levels of 1.01%, as tested by independent lab Digipath Labs, Inc. in Las Vegas.
“Because of our research background, we’re not willing to talk about things while we have only anecdotal evidence. But now, we have solid data that shows that the innovations that we have been working on for years are starting to bear fruit,” said Chief Science Office, Dr. Andrea Small-Howard.
This strain is the result of an ongoing research project and is one of many tangible results of the coordination of the three operating units— Life Sciences, Tissue Propagation, and Cultivation Labs. GB Sciences is a fully integrated cannabis company with three complementary operating units. The internal pipeline is now fully solidified; the Life Sciences division researches and develops the profile for a strain that is thought to be medicinally important; the Tissue Propagation team acquires the specified genetics and begins the propagation process to provide clean, healthy, starter plants so that verifiable and consistent results can be gained; the new plants then move into the Cultivation Labs precision controlled growing environment and are matured under stringently monitored growing conditions.
Mr. Kevin Kuethe, COO remarked, “GB Sciences is perfecting cannabis genetics. Everything we do is based in science and that involves testing and verifying every aspect of the process. Our precision controlled growing environment is now fully dialed in, and the high THC percentages and terpene levels in our premium genetics benefit both the medical formulation needs and the Adult Use market.”
Dr. Ulrich Reimann-Philipp, Chief Botanist stated, “We use our biotech tissue propagation to maximize the genetic potential of each strain. And our precision controlled growing environments are adjusted constantly to ensure that the full potential is delivered. We are now sure that we have found the conditions that allow us to get the most that each particular strain has to offer.”
Dr. Andrea Small-Howard, Chief Science Officer, said “The development of this strain is itself a remarkable achievement, but more importantly it shows that the GB Sciences divisional approach works, and works very efficiently. The excitement of coordinating a relatively large-scale effort in our relatively small company cannot be overstated; it proves that even while operating within the restrictive confines of Federal law, we can do something meaningful that will ultimately result in great advances in the treatment of many diseases for patients around the world. Research is in our corporate DNA.” (Source: PR Newswire)
We will treat the momentary pullback of the cannabis sector as a whole this week, following what was a rapid bullish run, as a temporary occurrence, at least until we get a clearer picture on the level to which Jeff Sessions intends to have federal officials interfere in a state’s rights matter. We maintain that 2018 is set to be a big year for the cannabis space, and will continue to cover these companies accordingly. Stay locked to Street Register for updates, and we’ll deliver important developments on GBLX as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!
Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in GBLX stock, short or long.